A Comparison of Therapies for Juvenile Idiopathic Arthritis
Researchers from the Netherlands compare three treatment options for patients with recent onset, non-systemic juvenile idiopathic arthritis.
Genetic Link Found Between Pediatric and Adult Arthritis
Researchers writing in Annals of the Rheumatic Diseases say they have identified a link between juvenile idiopathic arthritis and adult rheumatoid arthritis.
Genetic Differences by Type of Juvenile Idiopathic Arthritis
Genetic risk factors for systemic juvenile idiopathic arthritis are uniquely different from other types of juvenile idiopathic arthritis, a study shows.
Malignancies in JIA not Linked to TNFi Treatment
UAB research shows no “marked incremental increase in incident malignancies” after treatment with TNFi therapy as compared to malignancy rates associated with juvenile idiopathic arthritis.
Adalimumab-atto: It’s Indications and Key Takeaways
In this slideshow, we summarize the newly approved indications for Amgen's new biosimilar, adalimumab-atto (Amjevita) and, we highlight key points as stated by Amgen researchers.
Treg Cells Implicated in JIA
Treg cells are more prevalent in patients with juvenile idiopathic arthritis and active inflammation, as compared to patients in remission.
Moms with Juvenile Arthritis at Risk of Heart Disease
Pregnant women with juvenile arthritis are at heightened risk of heart disease, new research finds.
By clicking Accept, you agree to become a member of the UBM Medica Community.